DaVita/$DVA
1D1W1MYTD1Y5YMAX
Capital at risk
About DaVita
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
- Ticker
- $DVA
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 78,000
- Headquarters
- Denver, United States
- Website
- www.davita.com
DaVita Metrics
BasicAdvanced
$11B
14.87
$12.11
0.87
-
Price and volume
Market cap
$11B
Beta
0.87
52-week high
$247.49
52-week low
$101.00
Average daily volume
882K
Financial strength
Current ratio
1.467
Quick ratio
1.333
Long term debt to equity
1,190.417
Total debt to equity
1,241.986
Interest coverage (TTM)
3.67%
Profitability
EBITDA (TTM)
2,826.205
Gross margin (TTM)
32.36%
Net profit margin (TTM)
6.05%
Operating margin (TTM)
15.11%
Effective tax rate (TTM)
20.66%
Revenue per employee (TTM)
$180,000
Management effectiveness
Return on assets (TTM)
7.52%
Return on equity (TTM)
88.48%
Valuation
Price to earnings (TTM)
14.872
Price to revenue (TTM)
0.88
Price to book
-15.05
Price to tangible book (TTM)
-1.34
Price to free cash flow (TTM)
7.655
Free cash flow yield (TTM)
13.06%
Free cash flow per share (TTM)
23.52
Growth
Revenue change (TTM)
6.45%
Earnings per share change (TTM)
18.73%
3-year revenue growth (CAGR)
6.07%
10-year revenue growth (CAGR)
-0.24%
3-year earnings per share growth (CAGR)
33.80%
10-year earnings per share growth (CAGR)
21.55%
What the Analysts think about DaVita
Analyst ratings (Buy, Hold, Sell) for DaVita stock.
Analyst projections of the future price of DaVita stock.
Bulls say / Bears say
DaVita delivered a strong Q2 2026 with consolidated revenues of $3.554 billion and diluted EPS of $4.02, underpinning robust profitability. (PRNewswire)
DaVita generated $490 million in operating cash flow and $256 million in free cash flow in Q2 2026, supporting liquidity and strategic investments. (PRNewswire)
As of March 31, 2026, DaVita expanded its Integrated Kidney Care program to 62,600 patients representing $5.4 billion in annualized medical spend, accelerating its shift towards value-based care. (DaVita Newsroom)
A Trump administration proposal to keep Medicare Advantage payment rates flat for next year threatens reimbursement growth for roughly two-thirds of DaVita’s US sales, potentially constraining top-line expansion. (Bloomberg)
Management anticipates slightly negative revenue-per-treatment growth in the second half of 2026 due to lower commercial insurance mix and reduced phosphate binder revenue, limiting pricing leverage. (Yahoo Finance)
Normalized non-acquired treatment growth was just 0.3% year-over-year in Q2 2026, reflecting muted volume growth in DaVita’s core US dialysis services. (PRNewswire)
Data summarised monthly by Lightyear AI. Last updated on 20 Aug 2026.
DaVita Financial Performance
Revenues and expenses
DaVita Earnings Performance
Company profitability
Upcoming events
No upcoming events
DaVita News
AllArticlesVideos
Funds containing DaVita
AllEURGBPUSD
Fund name | Fund size | $DVA weighting |
|---|---|---|
iShares Ageing Population€AGED | €822M | 0.57% |
iShares S&P 500 Equal Weight£EWSP | £3.7B | 0.23% |
iShares S&P 500 Equal Weight€O4J0 | €4.3B | 0.17% |
iShares S&P 500 Health Care Sector€IUHE | €125M | 0.13% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.08% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.